Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

October 12, 2022

https://www.globenewswire.com/news-release/2022/10/12/2532698/0/en/Decibel-Therapeutics-Appoints-Kevin-F-McLaughlin-to-its-Board-of-Directors.html

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. McLaughlin to its Board of Directors.

Read more at globenewswire.com

Related news for (DBTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.